Table 3.

Efficacy results, PD-L1–positive population.

PD-L1 Expression ≥ 1%a
Atezolizumab + paclitaxel protein-boundPlacebo + paclitaxel protein-bound
Progression-free survivalb,c(n = 185)(n = 184)
 Events (%)136 (74)151 (82)
 Median, months7.4 (6.6, 9.2)4.8 (3.8, 5.5)
 Stratified HR (95% CI)d0.60 (0.48–0.77)
P<0.0001
Objective response rateb,c,e,fn = 185n = 183
 Number of responders (%)98 (53)60 (33)
 (95% CI)(45.5–60.3)(26.0–40.1)
 Complete response (%)17 (9)1 (<1)
 Partial response (%)81 (44)59 (32)
Duration of Responseb,c,fn = 98n = 60
 Median (months)9.26.2
 (95% CI)(7.5–11.9)(5.5–8.8)
  • Abbreviation: NE, not estimable.

  • aPD-L1 expression in tumor-infiltrating immune cells (IC).

  • bAs determined by investigator assessment.

  • cPer Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).

  • dStratified by presence of liver metastases, and by prior taxane treatment.

  • ePatients with measurable disease at baseline.

  • fConfirmed responses.